Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00539149
Registration number
NCT00539149
Ethics application status
Date submitted
2/10/2007
Date registered
4/10/2007
Date last updated
24/05/2010
Titles & IDs
Public title
Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children
Query!
Scientific title
Amoxycillin Versus Placebo for Resolution of Otitis Media With Effusion and Prevention of Acute Otitis Media With Perforation in Aboriginal Infants: a Randomised Controlled Trial.
Query!
Secondary ID [1]
0
0
NHMRC 954086
Query!
Secondary ID [2]
0
0
COMIT1
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
COMIT1
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Otitis Media
0
0
Query!
Condition category
Condition code
Ear
0
0
0
0
Query!
Other ear disorders
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Amoxycillin
Treatment: Drugs - Placebo equivalent to amoxycillin
Active comparator: 1 -
Placebo comparator: 2 -
Treatment: Drugs: Amoxycillin
50 mg/kg/day twice daily
Treatment: Drugs: Placebo equivalent to amoxycillin
50 mg/kg/d twice daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of children with middle ear effusion
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
end of intervention
Query!
Primary outcome [2]
0
0
Proportion of study visits at which middle ear effusion detected
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
during intervention
Query!
Secondary outcome [1]
0
0
Proportion of infants with tympanic membrane perforation
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
end of intervention
Query!
Secondary outcome [2]
0
0
Proportion of study visits with tympanic membrane perforation
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
during intervention
Query!
Secondary outcome [3]
0
0
Proportion of infants with nasopharyngeal colonisation with resistant Streptococcus pneumoniae
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
end of intervention
Query!
Secondary outcome [4]
0
0
proportion of infants withdrawn from study due to intervention adverse events
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
end of intervention
Query!
Eligibility
Key inclusion criteria
* Australian Aboriginal
* Living in participating remote community
* Less than 12 months of age
Query!
Minimum age
No limit
Query!
Query!
Maximum age
12
Months
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
* Less than 32 weeks gestation
* Chronic condition requiring continuous antibiotic
* Ear, nose or throat abnormality
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/1996
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2001
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
126
Query!
Recruitment in Australia
Recruitment state(s)
NT
Query!
Recruitment hospital [1]
0
0
Menzies School of Health Research - Darwin
Query!
Recruitment postcode(s) [1]
0
0
0811 - Darwin
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Menzies School of Health Research
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
National Health and Medical Research Council, Australia
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This clinical trial was conducted in a population where tympanic membrane perforation occurs in 60% infants in the first year of life. Nasopharyngeal colonisation (nasal contamination) with pathogenic bacteria occurs within weeks of life and predicts persistent middle ear infection throughout childhood. The trial aimed to assess whether twice daily antibiotics commencing at first detection of middle ear effusion would cure the infection and/or prevent disease progression, compared to placebo. The study was conducted in three remote Aboriginal communities in the Northern Territory of Australia. The annual birth cohort was 45. Aboriginal infants were seen as soon as possible after birth, and at 2 weekly intervals until middle ear effusion was detected by pneumatic otoscopy and tympanometry. Following consent, infants were randomised to either amoxycillin(50 mg/kg/d BD) or placebo equivalent for up to 24 weeks, or until normal middle ear status was detected at 2 consecutive monthly scheduled examinations. At monthly examinations the infant also had a general health check, parents were interviewed, child's medical record was reviewed, and nasopharyngeal swabs were collected.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00539149
Query!
Trial related presentations / publications
Leach AJ, Morris PS. Antibiotics for the prevention of acute and chronic suppurative otitis media in children. Cochrane Database Syst Rev. 2006 Oct 18;2006(4):CD004401. doi: 10.1002/14651858.CD004401.pub2. Morris PS, Leach AJ, Halpin S, Mellon G, Gadil G, Wigger C, Mackenzie G, Wilson C, Gadil E, Torzillo P. An overview of acute otitis media in Australian Aboriginal children living in remote communities. Vaccine. 2007 Mar 22;25(13):2389-93. doi: 10.1016/j.vaccine.2006.09.006. Epub 2006 Sep 22. Morris PS, Leach AJ, Silberberg P, Mellon G, Wilson C, Hamilton E, Beissbarth J. Otitis media in young Aboriginal children from remote communities in Northern and Central Australia: a cross-sectional survey. BMC Pediatr. 2005 Jul 20;5:27. doi: 10.1186/1471-2431-5-27. Leach AJ, Morris PS. Perspectives on infective ear disease in indigenous Australian children. J Paediatr Child Health. 2001 Dec;37(6):529-30. doi: 10.1046/j.1440-1754.2001.00729.x. Coates HL, Morris PS, Leach AJ, Couzos S. Otitis media in Aboriginal children: tackling a major health problem. Med J Aust. 2002 Aug 19;177(4):177-8. doi: 10.5694/j.1326-5377.2002.tb04727.x. No abstract available. Leach AJ, Morris PS, Smith-Vaughan H, Mathews JD. In vivo penicillin MIC drift to extremely high resistance in Serotype 14 Streptococcus pneumoniae persistently colonizing the nasopharynx of an infant with chronic suppurative lung disease: a case study. Antimicrob Agents Chemother. 2002 Nov;46(11):3648-9. doi: 10.1128/AAC.46.11.3648-3649.2002.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
John D Mathews, PhD, DSc.
Query!
Address
0
0
Menzies School of Health Research and University of Melbourne
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Leach AJ, Morris PS, Smith-Vaughan H, Mathews JD. ...
[
More Details
]
Results not provided in
https://clinicaltrials.gov/study/NCT00539149
Download to PDF